Nurix Therapeutics (NRIX) Gains from Investment Securities (2020 - 2025)
Historic Gains from Investment Securities for Nurix Therapeutics (NRIX) over the last 6 years, with Q3 2025 value amounting to $5.8 million.
- Nurix Therapeutics' Gains from Investment Securities changed N/A to $5.8 million in Q3 2025 from the same period last year, while for Nov 2025 it was $8.6 million, marking a year-over-year increase of 10930.12%. This contributed to the annual value of $32.5 million for FY2025, which is 69118.58% up from last year.
- Latest data reveals that Nurix Therapeutics reported Gains from Investment Securities of $5.8 million as of Q3 2025.
- Over the past 5 years, Nurix Therapeutics' Gains from Investment Securities peaked at $23.9 million during Q4 2023, and registered a low of -$12.8 million during Q4 2021.
- In the last 5 years, Nurix Therapeutics' Gains from Investment Securities had a median value of $2.8 million in 2024 and averaged $3.2 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 10390.97% in 2022, then skyrocketed by 553478.26% in 2024.
- Quarter analysis of 5 years shows Nurix Therapeutics' Gains from Investment Securities stood at -$12.8 million in 2021, then skyrocketed by 141.16% to $5.3 million in 2022, then surged by 354.03% to $23.9 million in 2023, then plummeted by 88.25% to $2.8 million in 2024, then skyrocketed by 105.91% to $5.8 million in 2025.
- Its Gains from Investment Securities was $5.8 million in Q3 2025, compared to $2.8 million in Q4 2024 and $1.3 million in Q2 2024.